News | Intravascular Imaging | October 18, 2020

NIRS-IVUS Imaging Can Help Identify High-Risk Plaques That Can Lead to Adverse Outcomes

Results from PROSPECT II Reported at 2020 TCT Connect virtual meeting

Illustration showing how the near-infrared spectroscopy (NIRS) intravascular ultrasound (IVUS), of NIRS-IVUS, intracoronary imaging system can help identify angiographically non-obstructive lesions with high-risk characteristics for future adverse cardiac outcomes. The system can identify unstable, vulnerable plaques. #TCTconnect #TCT2020

Illustration showing how the near-infrared spectroscopy (NIRS) intravascular ultrasound (IVUS), of NIRS-IVUS, intracoronary imaging system can help identify angiographically non-obstructive lesions with high-risk characteristics for future adverse cardiac outcomes. The system can identify unstable, vulnerable plaques.


October 18, 2020 – New data from the PROSPECT II study shows that near-infrared spectroscopy (NIRS) intravascular ultrasound (IVUS), of NIRS-IVUS, intracoronary imaging can help identify angiographically non-obstructive lesions with high-risk characteristics for future adverse cardiac outcomes.

Findings were reported today at 2020 Transcatheter Cardiovascular Therapeutics (TCT) Connect virtual symposium of the Cardiovascular Research Foundation (CRF).

“In PROSPECT II, lipid-rich plaques, as detected by NIRS, identified angiographically mild non-flow limiting lesions responsible for future coronary events,” said David Erlinge, M.D., Ph.D. Erlinge is professor, Department of Cardiology, clinical sciences, Lund University at Skane University Hospital in Sweden. “High lipid content, along with large plaque burden and small lumen area, may be added as prognostic indices of vulnerable plaques that put patients at risk for adverse outcomes. Further studies prospectively utilizing this information are warranted to improve outcomes for high-risk patients with coronary artery disease.”

Acute coronary syndromes most often arise from rupture and thrombosis of lipid-rich atherosclerotic plaques that develop in the setting of systemic inflammation. In the PROSPECT study, a large plaque burden or small lumen area assessed by IVUS identified angiographically mild lesions at increased risk to cause future coronary events. While lipid-rich fibro-atheromas identified by IVUS can be predictive, plaque interpretation with this technique is not as precise.

Lipid content may be more accurately measured by NIRS. Recent studies have suggested that lipid-rich plaques detected by intracoronary NIRS imaging are associated with adverse outcomes. Identifying these “vulnerable” plaques before they progress may help to inform pharmacologic or other strategies to stabilize the plaque.

An example if NIRS-IVUS intravascular imaging technology from the PROSPECT II trial showing 3 lesions in coronary artery and the technology chemogram showing areas of high lipid content in the vessel wall in yellow. #TCTconnect #TCT2020

An example if NIRS-IVUS intravascular imaging technology from the PROSPECT II trial showing 3 lesions in coronary artery and the technology chemogram showing areas of high lipid content in the vessel wall in yellow. 

 

PROSPECT II was an investigator-sponsored multicenter, prospective, natural history study conducted at 16 centers in Sweden, Denmark and Norway to validate the use of NIRS and IVUS imaging in identifying non-obstructive lipid-rich plaques that are prone to cause future cardiac events.

After successful treatment of all flow-limiting lesions in patients with recent myocardial infarction, imaging of all three coronary arteries was performed with a combination NIRS-IVUS catheter. The lipid content of “non-culprit” lesions was assessed by NIRS, and IVUS assessment was also performed. The primary outcome was the covariate-adjusted rate of major adverse cardiac events (the composite of cardiac death, myocardial infarction, unstable angina, or progressive angina) adjudicated to have arisen from non-culprit lesions. The relationship between plaques with high lipid content, large plaque burden, and small lumen areas and patient-level and lesion-level events were tested hierarchically.

A total of 3,629 untreated non-culprit lesions were prospectively characterized in 898 patients with myocardial infarction. Adverse events within four years occurred in 13.2% of patients, with a total of 8% of events arising from untreated non-culprit lesions with mean baseline diameter stenosis 46.9%. The presence of highly lipidic lesions was an independent predictor of patient-level non-culprit events (adjusted OR 2.27; 95% CI 1.25-4.13) and lesion-specific events (adjusted OR 7.83; 95% CI 4.12-14.89). Large plaque burden and small lumen areas were also independent predictors of adverse events.

The PROSPECT II trial was funded by research grants from Abbott Vascular, Infraredx and The Medicines Company. Erlinge reported the following disclosures: speaker fees from Amgen, AstraZeneca, Bayer, and Chiesi; and fees for Advisory Boards from Bayer, Boehringer Ingelheim, and Sanofi. 

For more information: www.tctconference.com

 

Related NIRS Content:

VIDEO: Near Infrared Spectroscopy Detects, Aids Risk Assessment of Vulnerable Plaques — Interview with Ron Waksman, M.D. 

NIRS-IVUS Detects Patients and Plaques Vulnerable to Subsequent Adverse Coronary Events - TCT 2019 late-breaking study

Find additional TCT 2020 news, video and late-breaking studies

Related Content

News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) ...

Home June 24, 2021
Home
News | Cardiovascular Clinical Studies

January 27, 2021 — A New York Institute of Technology research team has secured a five-year $1.8 million grant from the ...

Home January 27, 2021
Home
News | Cardiovascular Clinical Studies

July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to ...

Home July 22, 2020
Home
News | Cardiovascular Clinical Studies

July 1, 2020 — Carag AG announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption ...

Home July 01, 2020
Home
News | Cardiovascular Clinical Studies

January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special ...

Home January 20, 2020
Home
News | Cardiovascular Clinical Studies

Environmental and lifestyle issues were popular this year, with pick up from both European Society of Cardiology (ESC) ...

Home December 23, 2019
Home
News | Cardiovascular Clinical Studies

November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have ...

Home November 26, 2019
Home
News | Cardiovascular Clinical Studies

July 10, 2019 — The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During ...

Home July 10, 2019
Home
News | Cardiovascular Clinical Studies

July 3, 2019 — The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to ...

Home July 03, 2019
Home
News | Cardiovascular Clinical Studies

November 19, 2018 — The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent ...

Home November 19, 2018
Home
Subscribe Now